ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- ASIT biotech obtains large majority shareholder support for its continuity Wednesday, 27 May 2020
- ASIT Biotech applies for an extension of its reprieve Tuesday, 26 May 2020
- ASIT biotech postpones the publication of its 2019 annual report Sunday, 03 May 2020 All ASIT news